Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palladone Phased Launch Should Collect One Year Of Abuse Data, Cmte. Says

Executive Summary

The first phase of launch for Purdue's Palladone (hydromorphone) should collect data on abuse and diversion for a year, FDA's Anesthetic & Life Support Advisory Committee recommended Sept. 10

You may also be interested in...



Purdue Palladone Phased Launch To Begin In First Half 2005

Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005

Purdue Palladone Phased Launch To Begin In First Half 2005

Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005

Schedule II Drug Prescribing Would Require CME Under FDA, DEA Proposal

FDA and the Drug Enforcement Administration are encouraging legislation to require continuing medical education for renewal of DEA registration to prescribe Schedule II drugs

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel